The European Society for Blood and Marrow Transplantation (EBMT) is participating in World Lymphoma Awareness Day (WLAD) to increase awareness of this commonly diagnosed blood cancer.
The EBMT takes the opportunity of the Lymphoma awareness day recognised across the globe every year on Sept. 15th to highlight that malignant lymphoma can be cured by stem cell transplantation.
A recent study published in the Journal of Clinical Oncology* reveals for the first time that advanced-stage cutaneous T cell lymphoma (CTCL) can be cured by allogeneic stem cell transplantation. CTCL is a malignant illness which cannot be eradicated by chemotherapy or other modern cancer treatments. Patients who suffer from this disorder usually die within a few years once it has reached an advanced stage. Allogeneic stem cell transplantation (SCT) is a treatment which relies on transferring immune cells from a healthy donor to a cancer patient. The healthy immune cells expand in their new host and help to fight back his cancer cells. Because advanced CTCL is a very rare malignancy, it needs international cooperation to explore complex treatments such as SCT. Here the European Society for Blood and Marrow Transplantation (EBMT) comes into play. The EBMT is an organization of 4,323 members based in 563 transplant centres in 57 countries worldwide which collect detailed data of all performed SCT procedures. Over the years, more than 120,000 stem cell transplants for lymphoma have been registered with the EBMT, allowing unique scientific studies in all types of lymphoma including very orphan subtypes such as advanced CTLC.
Peter Dreger, Chairman of the EBMT Lymphoma Working Party, underlines that: “The work of the EBMT has largely contributed to the development of SCT-based lymphoma therapies which represent the current standard treatment for many types of lymphoma today, and thereby has helped to cure thousands of patients from their cancer.”
*The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.5597